12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersJaguar Health (NASDAQ:JAGX) shares rose 25.3% to $0.11 during Tuesday's after-market session. The company's market cap stands at $31.1 million. aTyr Pharma (NASDAQ:LIFE) shares rose 10.45% to $
ATyr Pharma to Participate in April Investor Conferences
SAN DIEGO, April 01, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its p
WW, ATNM and XTIA Are Among Pre Market Gainers
Repligen Appoints Maggie A. Pax to Board of Directors
ATyr Pharma Full Year 2023 Earnings: Revenues Disappoint
ATyr Pharma Is Maintained at Outperform by RBC Capital
ATyr Pharma Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Outperform on ATyr Pharma, Lowers Price Target to $16
RBC Capital analyst Gregory Renza maintains aTyr Pharma (NASDAQ:LIFE) with a Outperform and lowers the price target from $19 to $16.
ATyr Pharma Inc (LIFE) Reports Full Year 2023 Financial Results and Corporate Progress
Analysts Offer Insights on Healthcare Companies: ATyr Pharma (LIFE), Conmed (CNMD) and Ascendis Pharma (ASND)
Buy Rating Affirmed for ATyr Pharma as Lead Candidate Efzofitimod Advances in Clinical Trials With Solid Financial Footing
Earnings Call Summary | ATyr Pharma(LIFE.US) Q4 2023 Earnings Conference
The following is a summary of the ATyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript:Financial Performance:ATyr Pharma ended 2023 with $101.7 million in cash, restricted cash, cash equivalents,
ATyr Pharma GAAP EPS of -$0.25 Misses by $0.01
ATyr Pharma 4Q Loss/Shr 25c >LIFE
ATyr Pharma 4Q Loss/Shr 25c >LIFE
Press Release: ATyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
aTyr Pharma Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update Phase 3 EFZO-FIT(TM) study of efzofitimod in pulmonary sarcoidosis anticipated to complete enrollment in
ATyr Pharma's Earnings Outlook
aTyr Pharma (NASDAQ:LIFE) is set to give its latest quarterly earnings report on Thursday, 2024-03-14. Here's what investors need to know before the announcement.Analysts estimate that aTyr Pharma wil
ATyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2023 Financial Results
Management to host conference call and webcast on March 14th at 5:00 pm EDT / 2:00 pm PDTSAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotechnology
We Think ATyr Pharma (NASDAQ:LIFE) Can Afford To Drive Business Growth
HC Wainwright & Co. Reiterates Buy on ATyr Pharma, Maintains $35 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates aTyr Pharma with a Buy and maintains $35 price target.
ATyr Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 02/21/2024 1713.47% HC Wainwright & Co. → $35 Reiterates Buy → Buy 09/21/2023 1713.47% HC Wainwright & Co.
ATyr Pharma Announces Expanded Access Program (EAP) for EFZO-FIT Clinical Trial Participants
aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the Company), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
No Data